Strategic focus Verve Therapeutics sits at the forefront of genetic cardiovascular therapies with a portfolio targeting PCSK9, ANGPTL3, and LPA to address ASCVD risk, offering multiple high-potential partnership or licensing opportunities with Lilly-backed backing and ongoing development programs.

Clinical programs Lead programs VERVE-102, VERVE-201, and VERVE-301 address lipoprotein drivers of atherosclerosis, indicating potential for collaboration in gene editing delivery, liver-targeted therapies, and long-term cardiovascular outcomes—areas of interest for specialty pharma and academic partnerships.

Financial health With substantial funding and reported revenue in the tens of millions range and a funding pool over four hundred million, Verve shows capacity for partnering on co-development, milestone-based deals, and capability to support expansion-focused initiatives.

Strategic partnerships As a wholly owned subsidiary of Eli Lilly, Verve offers co-development and potential co-commercialization pathways, plus access to Lilly’s resources, sales, and global reach for later-stage products and expanding geographies.

Market positioning Growing recognition as a top place to work and active participation in major biotech conferences signals strong talent and visibility; combined with a focus on next-generation PCSK9 therapies, this creates compelling storytelling for investor and payer engagement to drive adoption.